ArticlePloS one2009
Pseudomonas aeruginosa population structure revisited.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed, 294 citations in OpenAlex.
- Intrapulmonary percussive ventilation improves lung function in cystic fibrosis patients chronically colonized with Pseudomonas aeruginosa: a pilot cross-over study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Trial
- Enhanced in vivo fitness of carbapenem-resistant oprD mutants of Pseudomonas aeruginosa revealed through high-throughput sequencing.Proceedings of the National Academy of Sciences of the United States of America · 2013Trial
- L2 β-lactamase contributes to ceftolozane-tazobactam resistance inAntimicrobial agents and chemotherapy · 2026Article
- Liquid-phase milk turbidimetry enables rapid phenotyping of secreted protease activity inMicrobiology spectrum · 2026Article
- Global epidemiology of carbapenem-resistantJAC-antimicrobial resistance · 2026Review
- Smaller Genomes and Shorter Prophage Sequences Differentiate Clinical from Environmental Isolates ofbioRxiv : the preprint server for biology · 2026Article
- Beyond Resistance Genes:Life (Basel, Switzerland) · 2026Review
- Synergistic Bactericidal Effects of R- and F-Type Pyocin Cocktails Against ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- Genomic characterization of Pseudomonas aeruginosa clonal lineage ST162 isolated from bovine-milk in South Africa.BMC microbiology · 2026Article
- A novel mechanism of ceftolozane-tazobactam resistance inbioRxiv : the preprint server for biology · 2026Article
- Genomic and epidemiological identification of Pseudomonas aeruginosa transmission chains and in hospital ICUs.Genome biology · 2026Article
- Genetic diversity of Pseudomonas aeruginosa isolated from clinical samples with ISSR molecular marker in a tertiary care teaching hospital.Scientific reports · 2026Article
- Phenotypic heterogeneity in Pseudomonas aeruginosa virulence revealed through passive exposure in zebrafish (Danio rerio) and nematodes (Caenorhabditis elegans).Access microbiology · 2026Article
- Interference ofPharmaceuticals (Basel, Switzerland) · 2025Article
- PqsE has a conserved sequence, yet a variable impact inJournal of bacteriology · 2025Article
- Pseudomonas aeruginosa: ecology, evolution, pathogenesis and antimicrobial susceptibility.Nature reviews. Microbiology · 2025Review
- Multigenerational proteolytic inactivation of restriction upon subtle genomic hypomethylation in Pseudomonas aeruginosa.Nature microbiology · 2025Article
- New Insights inAntibiotics (Basel, Switzerland) · 2025Article
- Genetic Diversity in Antimicrobial Resistance Determinants Among Pathogenic Pseudomonas aeruginosa in India.Current microbiology · 2025Article
- Review
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
At present there are strong indications that Pseudomonas aeruginosa exhibits an epidemic population structure; clinical isolates are indistinguishable from environmental isolates, and they do not exhibit a specific (disease) habitat selection. However, some important issues, such as the worldwide emergence of highly transmissible P. aeruginosa clones among cystic fibrosis (CF) patients and the spread and persistence of multidrug resistant (MDR) strains in hospital wards with high antibiotic pressure, remain contentious. To further investigate the population structure of P. aeruginosa, eight parameters were analyzed and combined for 328 unrelated isolates, collected over the last 125 years from 69 localities in 30 countries on five continents, from diverse clinical (human and animal) and environmental habitats. The analysed parameters were: i) O serotype, ii) Fluorescent Amplified-Fragment Length Polymorphism (FALFP) pattern, nucleotide sequences of outer membrane protein genes, iii) oprI, iv) oprL, v) oprD, vi) pyoverdine receptor gene profile (fpvA type and fpvB prevalence), and prevalence of vii) exoenzyme genes exoS and exoU and viii) group I pilin glycosyltransferase gene tfpO. These traits were combined and analysed using biological data analysis software and visualized in the form of a minimum spanning tree (MST). We revealed a network of relationships between all analyzed parameters and non-congruence between experiments. At the same time we observed several conserved clones, characterized by an almost identical data set. These observations confirm the nonclonal epidemic population structure of P. aeruginosa, a superficially clonal structure with frequent recombinations, in which occasionally highly successful epidemic clones arise. One of these clones is the renown and widespread MDR serotype O12 clone. On the other hand, we found no evidence for a widespread CF transmissible clone. All but one of the 43 analysed CF strains belonged to a ubiquitous P. aeruginosa "core lineage" and typically exhibited the exoS(+)/exoU(-) genotype and group B oprL and oprD alleles. This is to our knowledge the first report of an MST analysis conducted on a polyphasic data set.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.